In Japan, the PMDA-approved package insert for CBZ has been modified to incorporate more information regarding the HLA-A*31:01 allele [38], while Taiwan recommended using the HLA-B*15:02 testing to prevent CBZ-induced SJS-TEN [39]. This evidence concerns the gene HLA-B and toxic epidermal necrolysis.